Publication | Open Access
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
636
Citations
15
References
2012
Year
The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropin-secreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1